KURA Q3 2022 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$36M

EPS (Diluted)

$-0.53

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$448M

Total Liabilities

$28M

Stockholders' Equity

$420M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$34M	-8.7%
Net Income	-$36M	-$33M	-6.4%